AU2011234644B2 - PKC inhibitors for the treatment of B-cell lymphoma having chronic active B-cell-receptor signalling - Google Patents

PKC inhibitors for the treatment of B-cell lymphoma having chronic active B-cell-receptor signalling Download PDF

Info

Publication number
AU2011234644B2
AU2011234644B2 AU2011234644A AU2011234644A AU2011234644B2 AU 2011234644 B2 AU2011234644 B2 AU 2011234644B2 AU 2011234644 A AU2011234644 A AU 2011234644A AU 2011234644 A AU2011234644 A AU 2011234644A AU 2011234644 B2 AU2011234644 B2 AU 2011234644B2
Authority
AU
Australia
Prior art keywords
cell lymphoma
cell
pkc
inhibitor
dione
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011234644A
Other languages
English (en)
Other versions
AU2011234644A1 (en
Inventor
Walter Schuler
Frank P. Stegmeier
Markus Warmuth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2011234644A1 publication Critical patent/AU2011234644A1/en
Application granted granted Critical
Publication of AU2011234644B2 publication Critical patent/AU2011234644B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/499—Spiro-condensed pyrazines or piperazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2011234644A 2010-03-30 2011-03-28 PKC inhibitors for the treatment of B-cell lymphoma having chronic active B-cell-receptor signalling Ceased AU2011234644B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US31901310P 2010-03-30 2010-03-30
US61/319,013 2010-03-30
US201061425525P 2010-12-21 2010-12-21
US61/425,525 2010-12-21
PCT/EP2011/054709 WO2011120911A1 (en) 2010-03-30 2011-03-28 Pkc inhibitors for the treatment of b-cell lymphoma having chronic active b-cell-receptor signalling

Publications (2)

Publication Number Publication Date
AU2011234644A1 AU2011234644A1 (en) 2012-10-11
AU2011234644B2 true AU2011234644B2 (en) 2014-07-17

Family

ID=44710357

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011234644A Ceased AU2011234644B2 (en) 2010-03-30 2011-03-28 PKC inhibitors for the treatment of B-cell lymphoma having chronic active B-cell-receptor signalling

Country Status (12)

Country Link
US (1) US8748428B2 (https=)
EP (1) EP2552428A1 (https=)
JP (1) JP2013523678A (https=)
KR (2) KR101461767B1 (https=)
CN (1) CN102821759A (https=)
AR (1) AR080737A1 (https=)
AU (1) AU2011234644B2 (https=)
BR (1) BR112012024585A2 (https=)
CA (1) CA2795456A1 (https=)
MX (1) MX2012011341A (https=)
RU (1) RU2012146083A (https=)
WO (1) WO2011120911A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3018133T3 (en) 2011-11-30 2025-05-14 Univ Emory Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae
KR101723786B1 (ko) 2014-03-28 2017-04-06 가톨릭대학교 산학협력단 Ｉｌ―２１을 발현하는 중간엽 줄기세포를 포함하는 ｂ 세포 림프종 예방 또는 치료용 조성물
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
AU2017295858A1 (en) 2016-07-14 2019-01-24 Mingsight Pharmaceuticals, Inc. Treatment of cancer
CN110496223B (zh) * 2018-05-17 2021-09-10 复旦大学附属肿瘤医院 一种治疗非霍奇金氏淋巴瘤的药物组合物
WO2020092924A1 (en) * 2018-11-02 2020-05-07 Board Of Regents, The University Of Texas System Combination therapy for the treatment of egfr tyrosine kinase inhibitor resistant cancer

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489608A (en) 1989-12-21 1996-02-06 Goedecke Aktiengesellschaft Indolocarbazole derivatives and the use thereof
US5475085A (en) 1991-02-07 1995-12-12 Molecumetics, Ltd. Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
PT657458E (pt) 1993-12-07 2002-02-28 Lilly Co Eli Inibidores de proteina cinase c
US5545636A (en) 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
CA2179650C (en) 1993-12-23 2007-10-30 William Francis Heath, Jr. Bisindolemaleimides and their use as protein kinase c inhibitors
SI0776895T1 (en) 1995-11-20 1999-04-30 Eli Lilly And Company Protein kinase C inhibitor
EP2070921A1 (en) * 2000-11-07 2009-06-17 Novartis Ag Indolylmaleimide derivatives as protein kinase c inhibitors
US6645970B2 (en) * 2000-11-07 2003-11-11 Novartis Ag Indolylmaleimide derivatives
PT1478648E (pt) 2002-02-01 2014-07-15 Ariad Pharma Inc Compostos contendo fósforo e suas utilizações
TW200918046A (en) 2002-04-03 2009-05-01 Novartis Ag Indolylmaleimide derivatives
BRPI0409263A (pt) 2003-04-09 2006-03-28 Millennium Pharm Inc composto; composição farmacêutica; método para tratar uma doença mediada por ikk e método para inibir ikk em um paciente que dele necessita
GB0308466D0 (en) 2003-04-11 2003-05-21 Novartis Ag Organic compounds
WO2005041953A1 (en) 2003-10-24 2005-05-12 Eli Lilly And Company Bisindolyl maleimides useful for treating prostate cancer and akt-mediated diseases
EP1799699A1 (en) 2004-10-13 2007-06-27 Wyeth Analogs of 17-hydroxywortmannin as pi3k inhibitors
CA2599320A1 (en) 2005-02-25 2006-08-31 Kudos Pharmaceuticals Limited Hydrazinomethyl, hydr zonomethyl and 5-membered heterocylic compounds which act as mtor inhibitors and their use as anti cancer agents
JP2008531538A (ja) 2005-02-25 2008-08-14 クドス ファーマシューティカルズ リミテッド ２，４−ジアミノ−ピリドピリミジン誘導体とｍＴＯＲ阻害剤としてのその使用
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
MX2008000463A (es) 2005-07-11 2008-03-11 Novartis Ag Derivados de indolil-maleimida.
JP5191391B2 (ja) 2005-11-01 2013-05-08 ターゲジェン インコーポレーティッド キナーゼのビ−アリールメタ−ピリミジン阻害剤
JP5161102B2 (ja) 2005-11-22 2013-03-13 クドス ファーマシューティカルズ リミテッド ｍＴＯＲ阻害剤としてのピリドピリミジン、ピラゾピリミジンおよびピリミドピリミジン誘導体
GB0526246D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
EP1979325A1 (en) 2006-01-11 2008-10-15 AstraZeneca AB Morpholino pyrimidine derivatives and their use in therapy
CA2659851C (en) 2006-08-23 2014-02-25 Kudos Pharmaceuticals Limited 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
MX2009005950A (es) 2006-12-07 2009-10-12 Genentech Inc Compuestos inhibidores de fosfoinositido 3-quinasas y metodos de uso.
AR066879A1 (es) 2007-06-08 2009-09-16 Novartis Ag Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus
EP2205242B1 (en) 2007-09-12 2015-04-15 Genentech, Inc. Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
JP5348725B2 (ja) 2007-10-25 2013-11-20 ジェネンテック， インコーポレイテッド チエノピリミジン化合物の製造方法
CA2730930C (en) 2008-07-16 2015-01-13 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Abrams, ST et al (2007) Blood. Volume 109. Pages 1193-1201 *
Davis, RE et al (2010) Nature. Volume 463. Pages 88-92 *
Rossi, RM et al (2005) Blood (ASH Annual Meeting Abstracts). Volume 106: Abstract 1483 *
Rossi, RM et al (2008) Blood (ASH Annual Meeting Abstracts). Volume 112: Abstract 1595 *
Su, TT (2002) Nature Immunology. Volume 3 (8). Pages 780-786 *

Also Published As

Publication number Publication date
MX2012011341A (es) 2012-11-12
EP2552428A1 (en) 2013-02-06
WO2011120911A1 (en) 2011-10-06
JP2013523678A (ja) 2013-06-17
AU2011234644A1 (en) 2012-10-11
US20110245256A1 (en) 2011-10-06
KR101461767B1 (ko) 2014-11-13
KR20140107685A (ko) 2014-09-04
KR20120133389A (ko) 2012-12-10
CN102821759A (zh) 2012-12-12
AR080737A1 (es) 2012-05-02
BR112012024585A2 (pt) 2016-05-31
RU2012146083A (ru) 2014-05-10
US8748428B2 (en) 2014-06-10
CA2795456A1 (en) 2011-10-06

Similar Documents

Publication Publication Date Title
CN105849110B (zh) 使用溴结构域和额外终端(bet)蛋白抑制剂的用于癌症的组合疗法
AU2012219395B2 (en) mTOR/JAK inhibitor combination therapy
KR101886006B1 (ko) 돌연변이체 c-kit의 억제 방법
AU2011234644B2 (en) PKC inhibitors for the treatment of B-cell lymphoma having chronic active B-cell-receptor signalling
CN117530948A (zh) 化疗方案期间免疫反应的保持
US9358236B2 (en) Combinations of therapeutic agents for use in the treatment of neurodegenerative diseases
MX2009000713A (es) Inhibidores de jak para el tratamiento de trastornos mieloproliferativos.
WO2017156350A1 (en) Methods of cancer treatment
US9724354B2 (en) Combination of catalytic mTORC1/2 inhibitors and selective inhibitors of Aurora A kinase
KR20160020502A (ko) 제약 조합물
US20230201202A1 (en) Compositions and methods for sensitizing acute myeloid leukemias to chemotherapy
KR20170134462A (ko) Mdm2 저해제와 btk 저해제의 병용 치료법
CN113490497B (zh) 包括flt3抑制剂和低甲基化剂的用于治疗急性髓系白血病的药物组合物
AU2005312061A1 (en) Combinations comprising epothilones and protein tyrosine kinase inhibitors and pharmaceutical uses thereof
CN117794540A (zh) 用于治疗b细胞恶性肿瘤的组合物
WO2007143629A1 (en) Treatment of neurofibromatosis with inhibitors of a signal transduction pathway
WO2016209688A1 (en) Compositions for the treatment of cancer and uses thereof
KR20250151363A (ko) 골수증식성 신생물의 치료 방법
WO2014174478A1 (en) Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor
TW201139417A (en) Use of a PKC inhibitor

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired